



For immediate release

02 September 2011

Zilico shortlisted at FICCI HEAL 2011, India

Zilico's first product the APX 100 has been shortlisted by the FICCI HEAL 2011 Expert Committee, to present in a Special Session on "Showcasing Successful Innovations in Preventive Healthcare", during FICCI HEAL 2011 in New Delhi.

In countries where organised screening is still not established the APX system provides an opportunity to rapidly deploy screening programmes without the significant capital infrastructure costs of building and running pathology laboratories. In these countries the HPV molecular test may not be suitable for front-line screening because of costs and the time taken to generate results (~2 hours). In India over 300 million women are at risk from cervical cancer. There are 130,000 new cases of cervical cancer in India and ca75,000 women lose their lives to the disease. Current screening coverage is less than 5% of the population. Cervical cancer ranks as the 2nd most frequent cancer in women of all ages in Asia. The real-time results from APX system would enable treatment and referral decisions to be made immediately.

Commenting on the opportunity, Zilico's CEO Sameer Kothari – "We are very pleased to have the opportunity to present Zilico's product. FICCI is a great platform to raise the awareness of the APX system and we believe our product can help in diagnosing and managing women with the disease in emerging economies where the burden is the greatest".

For more information please contact: Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: sameer.kothari@zilico.co.uk

Notes for editors:

FICCI – Federation of Indian Chamber of Commerce & Industry

Established in 1927, FICCI is the largest and oldest apex business organisation in India. Its history is closely interwoven with India's struggle for independence and its subsequent emergence as one of the most rapidly growing economies globally. FICCI plays a leading role in policy debates that are at the forefront of social, economic and political change. Through its 400 professionals, FICCI is active in 39 sectors of the economy. FICCI's stand on policy issues is sought out by think tanks, governments and academia. Its publications are widely read for their in-depth research and policy prescriptions. FICCI has joint business councils with 79 countries around the world.

A non-government, not-for-profit organisation, FICCI is the voice of India's business and industry. FICCI has direct membership from the private as well as public sectors, including SMEs and MNCs, and an indirect membership of over 83,000 companies from regional chambers of commerce.

FICCI works closely with the government on policy issues, enhancing efficiency, competitiveness and expanding business opportunities for industry through a range of specialised services and global linkages. It also provides a platform for sector specific consensus building and networking.

Partnerships with countries across the world carry forward our initiatives in inclusive development, which encompass health, education, livelihood, governance, skill development, etc. FICCI serves as the first port of call for Indian industry and the international business community.

<http://www.ficci-heal.com/index.htm>

Zilico Limited

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two product applications are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.

The European multi-centre trial is designed to demonstrate the performance of its portable diagnostic device within a cervical cancer screening programme. The device is positioned as an adjunct to colposcopy to help accurately identify sites for biopsy. The trial has been carried out at three centres with international reputations in colposcopy and cervical cancer. A total of over 400 women were recruited into the trial and Zilico is now disseminating the data at key clinical meetings. Zilico will use the data from this trial to obtain a CE Mark for the use of the device as an adjunct to colposcopy.

<http://www.zilico.co.uk/>